LONDON, April 25 (Reuters) - European regulators said onFriday they had recommended approval of GlaxoSmithKline's melanoma drug Mekinist and also endorsed wider use ofBayer's Nexavar as a treatment for thyroid cancer.
Mekinist is one of several drugs being sold to Novartis under an asset swap deal.
Recommendations for marketing approval by the EuropeanMedicine Agency's Committee for Medicinal Products for Human Use(CHMP) are normally endorsed by the European Commission within acouple of months. (Reporting by Ben Hirschler; editing by Martinne Geller)
Glaxosmithkline (GSK)
